81470-51-1

Basic information

• Product Name: Z-Pyr-OtBu
• Synonyms: 1-Benzyl 2-(2-methyl-2-propanyl) (2S)-5-oxo-1,2-pyrrolidinedicarboxylate;1,2-Pyrrolidinedicarboxylic acid, 5-oxo-, 2-(1,1-dimethylethyl)1-(phenylmethyl) ester, (S)-;Z-Pyr-OtBu
• CAS NO: 81470-51-1
• Molecular Formula: C₁₇H₂₁NO₅
• Molecular Weight: 319.35234
• Mol File: 81470-51-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Z-Pyr-OtBu(CAS DataBase Reference)
• NIST Chemistry Reference: Z-Pyr-OtBu(81470-51-1)
• EPA Substance Registry System: Z-Pyr-OtBu(81470-51-1)

Safety Data

• Hazardous Substances Data: 81470-51-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Z-Pyr-OtBu is used as a key building block for the synthesis of various pharmaceuticals. Its unique structure and reactivity facilitate the preparation of complex molecules, which are crucial for drug development. The tert-butyl ester group provides protection to reactive intermediates, ensuring the successful synthesis of target compounds.
Used in Organic Material Synthesis:
In the field of materials science, Z-Pyr-OtBu serves as an essential component in the synthesis of organic materials. Its versatility in organic synthesis allows for the creation of novel materials with specific properties, such as improved stability or reactivity, which can be applied in various industries.
Used in Laboratory Research:
Z-Pyr-OtBu is widely used in laboratory settings for research purposes. Its unique properties make it an ideal candidate for studying various chemical reactions and mechanisms. Researchers can utilize Z-Pyr-OtBu to explore new synthetic routes, develop innovative methodologies, and gain insights into the fundamental aspects of organic chemistry.

Upstream product

• 540-88-5 acetic acid tert-butyl ester 
• 32159-21-0 Cbz-L-pGlu-OH 
• 57732-63-5 1-tert-butyl 5-methyl (2S)-2-{[(benzyloxy)carbonyl]amino}pentanedioate 
• 56-86-0 L-glutamic acid 
• 501-53-1 benzyl chloroformate 
• 35418-16-7 L-t-butyl pyroglutamate 
• 115-11-7 isobutene 
• 75-65-0 tert-butyl alcohol 
• 31139-36-3 dibenzyl dicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 2398-37-0 3-methoxyphenyl bromide 
• 100-59-4 phenylmagnesium chloride 
• 4124-76-9 N-(benzyloxycarbonyl)-L-glutamic acid anhydride 

Downstream Products

• 95022-60-9 benzyloxycarbonyl-L-glutamic acid α-tert-butyl ester γ-hydrazide 
• 113400-43-4 (S)-2-Benzyloxycarbonylamino-5-oxo-hept-6-enoic acid tert-butyl ester 
• 5891-45-2 (S)-2-(benzyloxycarbonylamino)pentanedioic acid tert-butyl ester 
• 124620-51-5 2-Benzyloxycarbonylamino-5-hydroxy-pentanoic acid tert-butyl ester 
• 5891-45-2 N-benzoyloxycarbonyl L-glutamic acid α-t-butylester 
• 138858-46-5 tert-butyl (2S)-1-(benzyloxycarbonyl)-4α-(phenylmethyl)pyroglutamate 
• 138858-33-0 tert-butyl (2S)-1-(benzyloxycarbonyl)-4α-(hydroxy(p-fluoroohenyl)methyl)pyroglutamate 
• 138858-33-0 tert-butyl (2S)-1-(benzyloxycarbonyl)-4β-(hydroxy(p-fluoroohenyl)methyl)pyroglutamate 
• 127949-78-4 t-butyl (2S)-1-benzyloxycarbonyl-4-(hydroxyphenylmethyl)pyroglutamate 
• 127949-78-4 tert-butyl (2S)-1-(benzyloxycarbonyl)-4α-(hydroxyphenylmethyl)pyroglutamate 
• 127949-78-4 tert-butyl (2S)-1-(benzyloxycarbonyl)-4β-(hydroxyphenylmethyl)pyroglutamate 
• 138858-32-9 tert-butyl (2S)-1-(benzyloxycarbonyl)-4α-(hydroxy(p-methoxyphenyl)methyl)pyroglutamate 
• 138858-32-9 tert-butyl (2S)-1-(benzyloxycarbonyl)-4β-(hydroxy(p-methoxyphenyl)methyl)pyroglutamate 
• 127949-79-5 t-butyl (2S)-1-benzyloxycarbonyl-4-(1-hydroxypropyl)pyroglutamate 

Relevant articles and documents

The synthesis of γ-Substituted Glutamic Acids via a Glutamic Acid γ-Enolate Synthon.

Treatment of α-t-butyl γ-methyl N-Z-glutamate (4) with lithium hexamethyldisilazide results in the regiospecific formation of the γ-anion, which reacts with electrophiles to give γ-substituted glutamic acid derivatives.

The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors

HCV NS5A inhibitors are the backbone of directly acting antiviral treatments against the hepatitis C virus (HCV). While these therapies are generally highly curative, they are less effective in some specific HCV patient populations. In the search for broader-acting HCV NS5A inhibitors that address these needs, we explored conformational restrictions imposed by the [7,5]-azabicyclic lactam moiety incorporated into daclatasvir (1) and related HCV NS5A inhibitors. Unexpectedly, compound 5 was identified as a potent HCV genotype 1a and 1b inhibitor. Molecular modeling of 5 bound to HCV genotype 1a suggested that the use of the conformationally restricted lactam moiety might have resulted in reorientation of its N-terminal carbamate to expose a new interaction with the NS5A pocket located between amino acids P97 and Y93, which was not easily accessible to 1. The results also suggest new chemistry directions that exploit the interactions with the P97-Y93 site toward new and potentially improved HCV NS5A inhibitors.

Selective Electrochemical Oxidation of Functionalized Pyrrolidines

A method for the selective electrochemical aminoxyl-mediated Shono-type oxidation of pyrrolidines to pyrrolidinones is described. These transformations show the high selectivity and functional group compatibility. This chemistry also demonstrates the use of an operationally simple ElectraSyn 2.0 and cost-effective stainless-steel electrode for the electrochemical oxidation of functionalized pyrrolidines.

PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES

Compounds of Formula (I) a or (I) b: including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these compounds and pharmaceutical compositions and their potential uses in the manufacture of a medicament in reducing reactive oxygen species (ROS) in a cell and for preventing, treating, ameliorating certain related disorder or a disease.

DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME

The currently available β-lactamase inhibitors are insufficient to inhibit the incessantly increasing β-lactamase, and novel β-lactamase inhibitors has been required today for the difficult treatment for bacterial infectious diseases caused by resistant bacteria which produce class C β-lactamase, extended-spectrum β-lactamase (ESBL) belonging to class A and D, or class A KPC-2 decomposing even carbapenem as a last resort for β-lactam antibiotic. A compound represented by the the formula (I), preparation process of the same, β-lactamase inhibitors and method for treating bacterial infectious diseases are provided.

DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS

The present invention relates to diazabicyclo[4.3.1 ]decane derivatives (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives are specific inhibitors of the FK506 binding proteins (FKBP's) and can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

The present invention relates to diazabicyclo[4.3.1]decane derivatives of formula (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives are inhibitors of the FK506 binding protein (FKBP's) and can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Stereoselective construction of the 5-hydroxy diazabicyclo[4.3.1]decane-2-one scaffold, a privileged motif for FK506-binding proteins

A stereoselective synthesis of a derivatized bicyclic [4.3.1]decane scaffold based on an acyclic precursor is described. The key steps involve a Pd-catalyzed sp3-sp2 Negishi-coupling, an asymmetric Shi epoxidation, and an intramolecular epoxide opening. Representative derivatives of this novel scaffold were synthesized and found to be potent inhibitors of the psychiatric risk factor FKBP51, which bound to FKBP51 with the intended molecular binding mode. (Chemical Equation Presented).

OPTICALLY-ACTIVE DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR MANUFACTURING SAME

Provided are an optically active diazabicyclooctane derivative defined by formula (F) below, which is useful as a pharmaceutical intermediate for β-lactamase inhibitor, and a process for preparing the same. In formula (F) above, R1 represents CO2R, CO2M, or CONH2, wherein R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or a 2,5-dioxopyrrolidin-1-yl group, and M represents a hydrogen atom, an inorganic cation, or an organic cation; and R2 represents a benzyl group or an allyl group.